ArticleAdvances in therapy2025

A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2-, Node-Positive, High-Risk Early Breast Cancer.

Alison Davie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.